Compare RNP & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNP | PCRX |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 984.5M | 1.0B |
| IPO Year | N/A | 2010 |
| Metric | RNP | PCRX |
|---|---|---|
| Price | $18.42 | $36.38 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $33.57 |
| AVG Volume (30 Days) | 136.8K | ★ 2.2M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 7.94% | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | N/A | $3.84 |
| Revenue Next Year | N/A | $4.73 |
| P/E Ratio | ★ N/A | $191.21 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $18.01 | $18.80 |
| 52 Week High | $21.88 | $36.67 |
| Indicator | RNP | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 83.59 |
| Support Level | $18.01 | $22.13 |
| Resistance Level | $20.82 | $36.67 |
| Average True Range (ATR) | 0.28 | 0.21 |
| MACD | 0.06 | 0.25 |
| Stochastic Oscillator | 65.36 | 97.60 |
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances. The Fund seeks to achieve its objectives through a portfolio of income producing common stock issued by REITs and preferred and other debt securities.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.